Healthcare / BiotechnologyNasdaqGM
$4.55
-0.14 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-69.6M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$227M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-47.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-113.1M · FCF $-103.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-113.1M | $-113.1M | $-78.1M | $-47.5M | $-67.6M |
| EBITDA | $-142.7M | $-142.7M | $-78.4M | $-51.3M | $-51.0M |
| EPS | -5.59 | -5.59 | -6.96 | -9.88 | -15.20 |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | — | — |
| Current Ratio | 13.78 | 13.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-103.3M | $-103.3M | $-69.6M | $-50.7M | $-45.7M |
| Returns | |||||
| ROE | -47.7% | -47.7% | -26.7% | -98.5% | -88.8% |
| Valuation | |||||
| P/B | 0.39 | 0.39 | 0.45 | 1.50 | 1.91 |
| Growth & Yield | |||||
| EPS Growth | 19.7% | 19.7% | 29.5% | 35.0% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.96 → -5.59
Residual
-43.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.